August 3rd 2023
Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.
Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.
July 28th 2023
Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.
Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.
July 20th 2023
The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.
Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.
July 13th 2023
Panelists review the presented patient profile and shares how they would have approached treatment.
Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.
July 10th 2023
Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.
Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.
July 3rd 2023
The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.
Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.
June 26th 2023
Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.
Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.